Safety and efficacy of cilostazol in the management of intermittent claudication | Zendy

YungWei Chi | Zendy; Carl J. Lavie | Zendy; Richard V. Milani | Zendy; Christopher J. White | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and efficacy of cilostazol in the management of intermittent claudication

Author(s) -

YungWei Chi,

Carl J. Lavie,

Richard V. Milani,

Christopher J. White

Publication year - 2008

Publication title -

vascular health and risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.892

H-Index - 68

eISSN - 1178-2048

pISSN - 1176-6344

DOI - 10.2147/vhrm.s3160

Subject(s) - cilostazol , medicine , intermittent claudication , pharmacotherapy , arterial disease , quality of life (healthcare) , claudication , intensive care medicine , psychological intervention , drug , physical therapy , aspirin , vascular disease , pharmacology , nursing , psychiatry

Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research